NasdaqGS:PHVSPharmaceuticals
Pharvaris (PHVS) Stock Could Be Far Below Fair Value After Phase 3 HAE Data
Pharvaris (NasdaqGS:PHVS) stock is in focus after the company reported detailed Phase 3 RAPIDe-3 and long-term CHAPTER-1 data for its oral hereditary angioedema therapy deucrictibant at the EAACI 2026 Congress.
See our latest analysis for Pharvaris.
Against this backdrop of detailed Phase 3 data and conference activity, Pharvaris stock has a 90 day share price return of 17.16% and a 1 year total shareholder return of 85.97%, suggesting building momentum as investors respond to the HAE program...